Multi-kinase inhibitors of RET, including cabozantinib and vandetanib, have modestly improved survival in patients with medullary thyroid cancer (MTC), but their toxicity may limit the durability of benefit [81,82]. Here, RET is linked to medullary thyroid gland carcinoma.